ISU 203
Alternative Names: ABX-1901; ISU-203Latest Information Update: 28 Aug 2023
At a glance
- Originator ISU Abxis
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Sphingomyelin phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dementia
Most Recent Events
- 16 Jul 2023 Pharmacodynamics data from preclinical studies in Alzheimer's disease presented at the Alzheimer's Association International Conference 2023 (AAIC-2023)
- 30 Jun 2023 Pharmacodynamics data from a preclinical studies in Dementia released by ISU Abxis
- 16 Jun 2023 Preclinical trials in Dementia in South Korea (Parenteral) as of June 2023 (ISU Abxis pipeline, June 2023)